Advertisement

Topics

Halozyme Therapeutics Company Profile

14:11 EST 17th December 2018 | BioPortfolio

Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's first hyaluronidase enzyme, recombinant human PH20 or rHuPH20, is the platform for three different products, including a medical device, a drug enhancement agent, and a therapeutic biologic. The company's initial products are being developed to offer safer and purer alternatives to existing slaughterhouse-derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme's highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine

Contact

Phone: 858.794.8889
Email: dramsay@halozyme.com


News Articles [699 Associated News Articles listed on BioPortfolio]

Halozyme Therapeutics, Inc. (HALO) Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin®) In Canada

Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin®) In Canada Halozyme Therapeutics, Inc. (HALO) today announced that Roche has received approval from Health Canada fo...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Halozyme Therapeutics, Inc. - HALO

NEW YORK, Nov. 29, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Halozyme Therapeutics, Inc. ("Halozyme" or the "Company") (NASDAQ: HALO). Such investors are...

Halozyme Therapeutics, Inc. (HALO) Appoints Bernadette Connaughton To Board Of Directors

Halozyme Appoints Bernadette Connaughton To Board Of Directors Halozyme Therapeutics, Inc. (HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the ap...

Halozyme, Edico CEOs Among San Diego’s Entrepreneurs of the Year

Helen Torley, who was highlighted in 2016 as the only female CEO of a public life sciences company in San Diego, was recognized last week for her operational excellence at Halozyme Therapeutics (NASDA...

Halozyme enrols 150 of 570 patients for Phase III pancreatic cancer trial

Halozyme Therapeutics’ Phase III HALO-301 trial investigating PEGPH20 for first-line pancreatic cancer with high levels of tumour hyaluronan (HA-high) has so far enrolled...Read More... The post ...

Health Canada approves subcutaneous treatment for breast cancer

Halozyme Therapeutics announced that a subcutaneous formulation of trastuzumab created with Halozymeâs technology, for the treatment of breast cancer, has received approval from Health Canada.

Halozyme Licenses New ENHANZE Targets For $25 Million Upfront Payment, Future Milestones And Royalties

SAN DIEGO, Oct. 30, 2018 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that it has l...

Halozyme Therapeutics, Inc. 2018 Q3 - Results - Earnings Call Slides

PubMed Articles [458 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development.

Clinical Trials [164 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1286 Associated Companies listed on BioPortfolio]

Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery m...

Halozyme Therapeutics

Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalm...

Baxter International Inc. and Halozyme Therapeutics, Inc.

Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cance...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

More Information about "Halozyme Therapeutics" on BioPortfolio

We have published hundreds of Halozyme Therapeutics news stories on BioPortfolio along with dozens of Halozyme Therapeutics Clinical Trials and PubMed Articles about Halozyme Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Halozyme Therapeutics Companies in our database. You can also find out about relevant Halozyme Therapeutics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record